

Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study

Shiwani Mahajan, MBBS, MHS;^{1,2} Rajesh Srinivasan, PhD;³ Carrie A. Redlich, MD, MPH;⁴
Sara K. Huston, BS;³ Kelly M. Anastasio, COC;⁵ Lisa Cashman, MPH;⁶ Dorothy S. Massey,
BA;¹ Andrew Dugan, MS;³ Dan Witters, MS;³ Jenny Marlar, PhD;³ Shu-Xia Li, PhD;¹ Zhenqiu
Lin, PhD;^{1,2} Domonique Hodge, PhD;³ Manas Chattopadhyay, PhD;³ Mark D. Adams, PhD;⁷
Charles Lee, PhD;⁷ Lokinendi V. Rao, PhD;^{6,8} Chris Stewart, BS;³ Karthik Kuppusamy, PhD,
MBA;⁶ Albert I. Ko, MD;⁹ Harlan M. Krumholz, MD, SM^{1,2,10}

¹ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT

² Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of
Medicine, New Haven, CT

³ The Gallup Organization, Washington, DC

⁴ Yale Occupational and Environmental Medicine Program, Department of Internal Medicine,
Yale School of Medicine, New Haven, CT

⁵ Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT

⁶ Quest Diagnostics, Marlborough, MA

⁷ The Jackson Laboratory for Genomic Medicine, Farmington, CT

⁸ Department of Pathology, University of Massachusetts Medical School, Worcester, MA

⁹ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,
CT

¹⁰ Department of Health Policy and Management, Yale School of Public Health, New Haven, CT

Address for correspondence:

Harlan M. Krumholz MD, SM

1 Church Street, Suite 200, New Haven, CT 06510 USA

Telephone: 203-764-5885; Fax: 203-764-5653

Email: harlan.krumholz@yale.edu; Twitter: @hmkyale

Word count: 2675 (main text)

Key words: Seroprevalence, SARS-CoV-2, COVID-19, Antibodies, Connecticut

ABSTRACT

Background: A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population, however, most existing reports have used a convenience sample, which may bias their estimates.

Methods: We sought a representative sample of Connecticut residents, aged ≥ 18 years and residing in non-congregate settings, who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 29, 2020. We also oversampled non-Hispanic Black and Hispanic subpopulations. We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies and the prevalence of symptomatic illness and self-reported adherence to risk mitigation behaviors among this population.

Results: Of the 567 respondents (mean age 50 [± 17] years; 53% women; 75% non-Hispanic White individuals) included at the state-level, 23 respondents tested positive for SARS-CoV-2-specific antibodies, resulting in weighted seroprevalence of 4.0 (90% confidence interval [CI] 2.0–6.0). The weighted seroprevalence for the oversampled non-Hispanic Black and Hispanic populations was 6.4% (90% CI 0.9–11.9) and 19.9% (90% CI 13.2–26.6), respectively. The majority of respondents at the state-level reported following risk mitigation behaviors: 73% avoided public places, 75% avoided gatherings of families or friends, and 97% wore a facemask, at least part of the time.

Conclusions: These estimates indicate that the vast majority of people in Connecticut lack antibodies against SARS-CoV-2 and there is variation by race/ethnicity. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents to prevent resurgence of COVID-19 in this region.

INTRODUCTION

Connecticut was one of the first states in the United States (US) to be severely affected by Coronavirus Disease 2019 (COVID-19), with its first confirmed case of COVID-19 in early March. While almost 43,000 cases and 4,000 deaths were reported by June,¹ a seroprevalence study, which estimates the percentage of people with SARS-CoV-2 antibodies, may provide a more accurate estimate of the percent of Connecticut population with evidence of a prior infection from COVID-19.

Prior seroprevalence studies have estimated the spread of COVID-19 in the US.²⁻⁸ However, the majority have taken advantage of blood samples collected for other reasons or used a convenience sample, which limits their representativeness. The Centers for Disease Control and Prevention (CDC) conducted a seroprevalence survey in Connecticut using blood specimens collected at commercial laboratories.⁸ However, these specimens were produced as part of routine or sick visit, representing a biased sample. Moreover, this effort did not provide the reason for the blood collection nor information about recent symptomatic illness, underlying conditions, or relevant risk-mitigation behaviors, which may help predict detection of antibodies against SARS-CoV-2.

Accordingly, with support from the Connecticut Department of Public Health (DPH) and the CDC, we conducted the Post-Infection Prevalence (PIP) Study, a public health surveillance project to determine the seroprevalence of SARS-CoV-2 among adults residing in community-non-congregate settings in Connecticut before June. Specifically, we sought to understand prior spread at the state-level; collect information about symptomatic illness, risk factors for virus infection, and self-reported adherence to risk mitigation behaviors; compare our seroprevalence

estimates to available Connecticut estimates; and provide targeted estimates for the non-Hispanic Black and Hispanic populations.

METHODS

Study cohort

For the state-level seroprevalence estimate, from June 4 to June 23, 2020 we enrolled 735 adults residing in non-congregate settings (i.e. excluding individuals living in long-term care facilities, assisted living facilities, nursing homes, and prisons or jails) in Connecticut, aged ≥ 18 years, using a dual-frame Random Digit Dial (RDD) methodology.⁹ Additionally, from June 23 to July 22, 2020 we oversampled non-Hispanic Black (n=269) and Hispanic (n=341) individuals to provide more accurate estimates for these subpopulations. Details of the sample size calculation and RDD methodology are described in **eMethods 1**. Details of participant recruitment are described in **eMethods 2**. We contacted a total of 7305 respondents at the state-level, and successfully completed 735 interviews. We contacted a total of 12,508 respondents for the oversampled subpopulations, of whom 457 completed interviews.

The study was deemed not to be research by the Institutional Review Board at Yale University because of the public health surveillance activity exclusion and was approved by the Institutional Review Board at Gallup.

Survey components

Individuals selected were provided study details, and informed consent was obtained from all participants by trained interviewers. Participants were interviewed using a questionnaire that collected information on demographics, social determinants of health, history of influenza-

like-illness, symptoms experienced, and other COVID-19-related topics. The average survey time was 15 minutes.

Specimen collection and serology testing

Within 24-48 hours of completing the interview, respondents were contacted to schedule their blood draw appointment at their nearest Quest Diagnostics Patient Service Center (PSC). Up to 5 attempts were made to each household where the participant agreed to be tested. Upon confirmation that the participant had completed the test, an incentive payment of \$50 was sent as a gift card via email or mail. Beginning July 17, 2020, we offered participants an additional \$50 (for a total compensation of \$100) to incentivize completion of the serology test.

Of the 735 participants enrolled in the state-level estimate, 25 participants refused to participate when re-contacted for scheduling and 567 participants completed serology testing at 93 Quest Diagnostics PSCs throughout Connecticut between June 10 and July 29, 2020 (**eFigure 1**). Of the total 341 Hispanic and 269 non-Hispanic Black participants enrolled for the oversample estimate, 171 and 148 participants, respectively, completed serology testing (**eFigure 2**). The distribution of the timing of the blood draws is shown in **eFigure 3**.

Sera was obtained from samples collected in BD Hemogard serum separator tubes. All samples were processed at the Quest Diagnostics Marlborough Laboratory. Samples were run at room temperature using the primary collection tube. We measured IgG SARS-CoV-2 antibodies using Ortho-Clinical Diagnostics Vitros anti-SARS-CoV-2 IgG test, which detects antibodies against the spike glycoprotein of the virus.¹⁰ Antibody levels were expressed as the ratio of the chemiluminescence signal over the cutoff value, with a value ≥ 1.00 reported as positive.¹¹ The Ortho Vitros IgG test had a reported sensitivity and specificity of 90% and 100%, respectively.¹⁰

We validated the sensitivity of this test in a small subset of SARS-CoV-2 positive patients (n=36) with variable disease severity, using reverse transcription polymerase chain reaction testing as the gold standard.¹²

Additionally, given the concern about the accuracy of serology tests,¹³ we re-tested the negative samples from 5 high risk cities of Connecticut (i.e. Bridgeport, Hartford, New Haven, Stamford, and Waterbury) with the Abbott Architect SARS-CoV-2 IgG test that detects antibodies aimed at a different SARS-CoV-2 antigen (nucleocapsid protein).¹⁴

Finally, Quest Diagnostics provided results for all SARS-CoV-2 serology tests conducted throughout Connecticut in the same time period (i.e. June 10 and July 29, 2020) for comparison.

Statistical analysis

The sample data were weighted to approximate the Connecticut population (details described in **eMethods 3**). Briefly, the base weight assigned to each completed survey was derived as the product of inverse of the probability of selection and non-response adjustment. Next, post-stratification weighting adjustments were made to account for residual non-response and to match the weighted sample estimates to known population characteristics for Connecticut. Post-stratification weighting for state-level sample was carried out using raking (or Iterative Proportional Fitting) procedures to adjust for age, gender, race/ethnicity, and education. The categories chosen for weighting the oversample subpopulations were different from what was used for the state-level adjustments due to lower available sample sizes. To reduce the effect of extreme weights on sampling variance, final weights were trimmed. The margin of error (MOE) for this study was calculated at the 90% confidence level (CI) taking into consideration the design effect introduced by variability of weights on each survey estimate. Overall study

design effect as estimated by the Kish approximation equals 1.83, however, it varies by each survey estimate.

Next, the unweighted seroprevalence was calculated for both the overall state-level sample and the oversampled non-Hispanic Black and Hispanic subgroups. Finally, we estimated the weighted state-level seroprevalence and the MOE of these estimates, both overall and for subgroups with sufficient sample size. Subgroups with sample sizes <30 were too small to calculate accurate estimates and were thus not reported. We also estimated the MOE at 95% CI for the state-level estimates as a secondary outcome. We reported the weighted seroprevalence for non-Hispanic Black and Hispanic subgroups separately.

All statistical analyses were performed using SPSS 24.0 (SPSS, Inc. Chicago, IL) and R version 4.0.2. We considered 2-sided P-values <0.05 as statistically significant.

RESULTS

Population characteristics for the state-level sample

The final state-level sample included 567 respondents who completed both the survey and the serology test. The mean age of the weighted sample was 50.1 (± 17.2) years, 53% were women, and the majority (75%) were non-Hispanic White individuals. Other weighted and unweighted characteristics of the study sample are reported in Table 1.

Comparison of the unweighted demographic distribution of individuals who completed only the survey with those who completed both the survey and the antibody test has been provided in **eTable 1**. While the 2 groups were not significantly different in regional representation, a significantly higher number of younger, Hispanic and non-Hispanic Black individuals did not complete blood testing. However, our weighted study sample was closer to

the target sample in the distribution of subgroups by age, sex, race/ethnicity, education level, and health insurance (**Table 1**).

Symptoms and risk mitigation behaviors at the state-level

As shown in **Table 2**, cough, diarrhea, fever, sore throat and new onset loss of taste or smell was reported by 18%, 16%, 9%, 10%, and 5% respondents, respectively, at some point between March and June. About 16% individuals reported being tested for coronavirus previously, and of these, 12% reported testing positive.

The majority of respondents reported following risk mitigation practices, at least some of the time, since March, with 73% reporting having avoided public places and 75% reporting having avoided gatherings of family and friends. Notably, 97% respondents reported wearing mask outside their home at least part of the time. About 31% of all respondents reported having worked from home at least part of the time, representing 57% of working respondents. We compared the prevalence of symptomatic illness and risk mitigation behaviors among individuals who completed only the survey with those who completed the survey and the antibody test in **eTable 2**.

Seroprevalence of SARS-CoV-2 antibodies at the state-level

Seroprevalence estimates are shown in **Table 3**. Overall, 23 respondents tested positive for SARS-CoV-2 antibodies, yielding a weighted seroprevalence of 4.0% (90% CI 2.0–6.0). Among individuals who reported having symptomatic illness, those with fever, cough, sore throat, and diarrhea had a weighted seroprevalence of 32.4% (90% CI 15.1–49.7), 11.4% (90% CI 2.8–20.0), 10.3% (90% CI 0.0–21.0), and 6.9% (90% CI 0.0–14.4), respectively. Among the

25 individuals who reported loss of taste or smell, 14 individuals tested positive for SARS-CoV-2-specific antibodies.

Asymptomatic individuals had significantly lower weighted seroprevalence 0.6% (90% CI 0.0–1.3) compared with the overall state estimate, while those with ≥ 1 and ≥ 2 symptoms had a seroprevalence of 11.3% (90% CI 5.4–17.2) and 16.1% (90% CI 4.9–27.3), respectively (**Table 3**). The comparisons between other subgroups and the state estimates are presented in **eTable 3**. Additionally, seroprevalence estimates at 95% MOE have also been shown in **eTable 3**.

Among the 143 negative samples from 5 high risk cities of Connecticut that were re-tested with Abbott Architect serology assay, 142 (99.3%) samples tested negative. Additionally, of the total 25,274 antibody tests conducted by Quest Diagnostics in Connecticut during this time period, 2072 (8.4%) samples tested positive. Of the 11 respondents who reported testing positive for coronavirus, all tested positive for antibodies.

Characteristics and seroprevalence estimates among non-Hispanic Black and Hispanic subpopulations

For the subpopulation estimate, the final sample included 171 Hispanic (39.9 [± 15.5] years and 51% women) and 148 non-Hispanic Black (46.4 [± 13.0] years and 56% women) adults (**eTable 4**). Fever, cough, sore throat, diarrhea, and new loss of taste or smell was reported by 11%, 17%, 15%, 10%, and 8% of Hispanic participants and 4%, 10%, 5%, 4%, and 6% of Black participants (**Table 4**). About 37% of Hispanic and 31% of non-Hispanic Black individuals reported receiving a coronavirus test previously and nearly 6% of Hispanic and 4% non-Hispanic Black individuals reported testing positive for coronavirus. The prevalence of symptomatic

illness and risk mitigation behaviors among individuals who completed only the survey has been compared with those who completed both the survey and the antibody test in **eTable 5**.

The weighted seroprevalence among the Hispanic and non-Hispanic Black subpopulation, derived from both the random state sample and the oversample, was 19.9% (90% CI 13.2–26.6) and 6.4% (90% CI 0.9–11.9) respectively. The seroprevalence estimate for the Hispanic group was significantly higher than the overall state-level estimate.

DISCUSSION

Our study primarily shows that despite Connecticut being an early COVID-19 hotspot, the vast majority of people in Connecticut lack detectable antibodies to SARS-CoV-2. In addition, individuals who reported having symptomatic illness between March and June of 2020 had higher seroprevalence rates, but over 90% of these individuals did not have SARS-CoV-2-specific IgG antibodies. Also, a high percentage of people interviewed reported following risk mitigation strategies, which may be partly responsible for the reduction in the number of new COVID-19 cases being reported in Connecticut. Finally, the Hispanic subpopulation had a higher prevalence of SARS-CoV-2-specific antibodies as compared with the overall state-level estimate, suggesting that the burden of disease was higher in this subgroup.

Our findings are consistent with other reports of more selected Connecticut populations. The CDC conducted a seroprevalence study using commercial laboratory data and reported a seroprevalence of 4.9% (95% CI 3.6-6.5) between April 26 and May 3 and 5.2% (95% CI 3.8–6.6) between May 21 and May 26 in Connecticut.^{2,8} However, these estimates were from people who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick visit, and as such would be expected to be biased higher than estimates for the general

population. Similarly, data for all antibody tests conducted by Quest Diagnostics in Connecticut between June 10 and July 29, showed a seropositivity rate of 8.4%. Since these estimates were also among people who had a serology test done at a commercial laboratory, it is likely that these specimens were drawn from individuals who were more likely to suspect prior disease exposure than the general population.

Overall, our findings are consistent with other reports of population-level seroprevalence of SARS-CoV-2 in Europe and the US, although the burden of disease in these regions may have varied. A recent report from Spain,¹⁵ reported a seroprevalence of 4.6% (95% CI 4.3–5.0) and a population-based study from Switzerland,¹⁶ reported SARS-CoV-2 antibodies in <10% of the population. Reports from regions within the US have also shown similar numbers. A recent report from Indiana⁵ found a seropositivity rate of 1.01% (95% CI, 0.76–1.45) and a community seroprevalence survey from Atlanta⁴ estimated seroprevalence of 2.5% (95% CI, 1.4–4.5). Our findings of a higher burden of SARS-CoV-2 antibodies among Hispanic subgroups is also consistent with prior reports demonstrating that minority populations have been disproportionately affected by COVID-19.^{5,17}

There are several explanations for why our state-level estimates are lower than what one might expect given that Connecticut had nearly 43,000 positive cases and 4,000 COVID-19 deaths by June 1, 2020. First, the majority of those deaths were among residents of congregate facilities. Second, the response and serology testing rates may have influenced the result. Only 7% of those contacted by phone completed the survey and blood test and the recruited population differed from the targets. However, this is a standard response rate in studies seeking representative populations and was considered in weighting the data. It is also possible that those who were more likely to have a positive test failed to complete the blood draw in higher

proportions. However, this non-response was taken into account while weighting the sample. Third, there is some evidence suggesting a short-lived antibody response, especially among individuals with mild or asymptomatic illness,^{18,19} and it is possible that more people were infected who lost antibodies over time. However, recent studies suggest that the decline in this timeframe is small and antibody levels can remain stable for up to 120 days,^{20,21} and all 11 people who reported receiving a previous coronavirus test in our study tested positive for antibodies. Fourth, the accuracy of the serology tests has been a concern.¹³ However, 99% of the negative serology samples from the highest risk regions of Connecticut that we re-tested with Abbott Architect serology assay tested negative a second time.

Nevertheless, our findings are concordant with other studies in indicating that the vast majority of the population in Connecticut does not have detectable levels of antibodies against SARS-CoV-2. At present, we do not know whether anti-SARS-CoV-2 antibodies confer immunity. If such antibodies, as detected by ELISA, are a marker of immunity, then more than 95% of the people in Connecticut would be susceptible to the virus. Given low infection rates over the summer, these general estimates are still reasonable. As such, there is continued need for strong public health efforts encouraging Connecticut residents to adhere to risk mitigation behaviors so as to prevent a second wave of spread in the region.

Conclusion

Our findings indicate that even in one of the early hotspots of the SARS-CoV-2 outbreak in the US, most of the population does not have detectable antibodies against SARS-CoV-2, and as such, remains vulnerable to infection. Also, there is notable variation by race/ethnicity. People likely need to continue to be vigilant about practices that can slow the spread in order to prevent resurgence of the virus in these regions.

REFERENCES

1. CT Department of Public Health. COVID-19 Data Resources. <https://data.ct.gov/stories/s/COVID-19-data/wa3g-tfvc/>. Accessed September 22, 2020.
2. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med.* 2020.
3. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA.* 2020.
4. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies — Two Georgia Counties, April 28–May 3, 2020. *MMWR Morb Mortal Wkly Rep.* ePub: 21 July 2020.
5. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020. *MMWR Morb Mortal Wkly Rep.* ePub: 21 July 2020.
6. Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative Incidence and Diagnosis of SARS-CoV-2 Infection in New York. *Ann Epidemiol.* 2020.
7. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol.* 2020.
8. CDC. Commercial Laboratory Seroprevalence Survey Data. Coronavirus Disease 2019 (COVID-19): Serology Surveillance. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html>. Accessed September 22, 2020.
9. Cummings KM. Random Digit Dialing: A Sampling Technique for Telephone Surveys. *Public Opinion Quarterly.* 1979;43(2):233-244.

10. EUA Authorized Serology Test Performance. U.S. Food & Drug Administration. <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance>. Accessed September 22, 2020.
11. Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test. Instructions To Use. U.S. Food and Drug Administration. EUA Authorized Serology Test Performance. <https://www.fda.gov/media/136967/download>. Accessed September 22, 2020.
12. Mahajan S, Redlich CA, Wisnewski AV, et al. Performance of Abbott Architect, Ortho Vitros, and Euroimmun Assays in Detecting Prior SARS-CoV-2 Infection. *medRxiv*. 2020:2020.2007.2029.20164343.
13. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody Tests for Identification of Current and Past Infection with SARS-CoV-2. *Cochrane Database of Systematic Reviews*. 2020(6).
14. Abbott Architect SARS-CoV-2 IgG. Instructions To Use. U.S. Food and Drug Administration. EUA Authorized Serology Test Performance. <https://www.fda.gov/media/137383/download>. Accessed September 22, 2020.
15. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A Nationwide, Population-Based Seroepidemiological Study. *The Lancet*.
16. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Geneva, Switzerland (SEROCoV-POP): A Population-Based Study. *The Lancet*.
17. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *NEJM*. 2020;382(26):2534-2543.

18. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections. *Nat Med*. 2020.
19. Ibarondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *NEJM*. 2020.
20. Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. *medRxiv*. 2020:2020.2007.2014.20151126.
21. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *NEJM*. 2020.

ACKNOWLEDGEMENTS

We are thankful to Matt Cartter, Josh Geballe, and Deidre Gifford from the Connecticut Department of Public Health for their assistance with the funding. We are also thankful to Michael F. Murray, Saad B. Omer, Alan Gerber, Adam Wisnewski, Richard Torres, Nathan Grubaugh, Wade Schulz, Tesheia Johnson, Cesar Caraballo-Cordovez, Yuan Lu, Erica S. Spatz, and Karthik Murugiah from Yale University for their support. Finally, we are in debt to those who participated in the surveys and completed the serology test, and the many people at our organizations who spent countless hours ensuring the success of the project and contributing to the public's health.

FUNDING SOURCE: This project was supported by the Centers for Disease Control and Prevention through the CARES Act and the Beatrice Kleinberg Neuwirth Fund.

CONFLICTS OF INTEREST: Dr. Lee is an Adjunct Professor at The First Affiliated Hospital of Xi'an Jiaotong University. Dr. Ko reports grants from Bristol Myer Squib Foundation, Regeneron, and Serimmune, and honoraria from Bristol Myer Squib, outside the submitted work. Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the United States Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention

and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; is a consultant to FPrime; is a co-founder of HugoHealth, a personal health information platform; and is a co-founder of Refactor Health, an enterprise healthcare artificial intelligence-augmented data management company. The other co-authors report no potential competing interests.

Table 1. Sociodemographic and clinical characteristics of adults included in the study for the state-level estimate.

Characteristics	Unweighted N	Unweighted Proportion, %	Weighted Proportion, %	Target Percentage¹, %
Overall	567	-	567	-
Age group, years				
18-29	41	7.2%	13.1%	19.9%
30-44	90	15.9%	26.7%	22.9%
45-54	113	19.9%	18.6%	17.5%
55-64	134	23.6%	18.6%	18.1%
≥65	187	33.0%	23.0%	21.6%
Sex				
Men	244	43.0%	46.6%	48.1%
Women	323	57.0%	53.4%	51.9%
Race/Ethnicity				
Hispanic	49	8.6%	13.0%	14.4%
Non-Hispanic White	470	82.9%	74.9%	69.4%
Non-Hispanic Black	37	6.5%	9.6%	9.8%
Non-Hispanic Asian	9	1.6%	1.2%	4.7%
Non-Hispanic Other	5	0.9%	1.7%	1.7%
Education level				
Less than high school	7	1.2%	3.7%	9.3%
High school or GED	79	13.9%	33.2%	27.4%
Some college	131	23.1%	23.9%	26.5%
Bachelor's degree or more	350	61.7%	39.2%	36.8%
Income level				
Less than \$24,000	40	7.1%	11.3%	N/A
\$24,000 to \$59,999	104	18.3%	25.0%	N/A
\$60,000 to \$119,999	178	31.4%	30.1%	N/A
\$120,000 or more	195	34.4%	26.8%	N/A
Don't know/Refused	50	8.8%	6.8%	N/A
Health insurance				
Yes	554	97.7%	95.3%	94.0%
No	13	2.3%	4.7%	6.0%
Employment status				
Employed full-time	263	46.4%	45.2%	63.8%
Employed part-time	56	9.9%	10.0%	
Unemployed	43	7.6%	10.6%	3.5%
Retired/Student/Homemaker	175	30.9%	25.5%	N/A
Disabled	0	0.0%	0.0%	N/A
Unknown	30	5.3%	8.6%	N/A
Essential job (exempt from stay-at-home orders)				
Yes	140	24.7%	27.5%	N/A

No	169	29.8%	24.8%	N/A
Don't know/Refused/Not employed	258	45.5%	47.7%	N/A
Region/County				
Fairfield	126	22.2%	25.2%	25.8%
Hartford	157	27.7%	24.1%	24.9%
Litchfield	42	7.4%	5.5%	5.2%
Middlesex	34	6.0%	5.0%	4.7%
New Haven	131	23.1%	24.3%	24.1%
New London	41	7.2%	7.8%	7.6%
Tolland	20	3.5%	4.5%	4.4%
Windham	16	2.8%	3.6%	3.3%
Type of home				
Mobile home	2	0.4%	1.0%	N/A
Single family house or townhouse	447	78.8%	69.7%	N/A
Apartment or condo	112	19.8%	28.1%	N/A
Group facility	2	0.4%	0.3%	N/A
Don't know/Refused	4	0.7%	0.9%	N/A
Self-reported health status				
Excellent	177	31.2%	29.7%	N/A
Very good	223	39.3%	32.0%	N/A
Good	128	22.6%	26.9%	N/A
Fair	33	5.8%	9.2%	N/A
Poor	6	1.1%	2.3%	N/A
Chronic conditions				
Diabetes	64	11.3%	12.2%	N/A
Asthma, COPD or another lung disease	63	11.1%	16.7%	N/A
Heart disease	37	6.5%	6.9%	N/A
Cancer	72	12.7%	10.7%	N/A
High blood pressure	171	30.2%	30.5%	N/A
Immune compromised	46	8.1%	8.5%	N/A
Lived in Connecticut in past 12 weeks				
<6 weeks	9	1.6%	1.0%	N/A
6-10 weeks	13	2.3%	1.9%	N/A
11-12 weeks	543	95.8%	96.5%	N/A
Don't know/Refused	2	0.4%	0.6%	N/A
<p>¹ Source for age, sex, race, ethnicity, education, employment, county targets: American Community Survey 2018. Source for health insurance: Reference information for health insurance coverage is obtained from the Current Population Survey estimates, 2018. Target percentage is based on expected proportions for a perfectly random sample, based on credible external sources. Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; GED, General Educational Development test; N/A, Not Available.</p>				

Table 2. Prevalence of symptomatic illness, risk factors for possible exposure, and adherence to social-distancing behaviors since March 1, 2020 among the state-level population.

Characteristics	Unweighted N	Unweighted Proportion, %	Weighted Proportion, % (MOE)
Symptoms			
Fever	43	7.6%	8.7% (± 2.7)
Cough	84	14.8%	18.3% (± 3.5)
Sore throat	54	9.5%	10.1% (± 2.7)
New loss of taste or smell	25	4.4%	4.8 (± 2.0)
Diarrhea	70	12.3%	15.9% (± 3.2)
Risk Factors/Behaviors			
Received coronavirus test	90	15.9%	15.7% (± 3.5)
Tested positive for coronavirus	11	1.9%	1.9% (± 1.4)
Anyone in household (other than respondent) had symptoms of coronavirus	54	9.5%	10.2% (± 2.7)
Anyone in household (other than respondent) tested positive for coronavirus	16	2.8%	3.7% (± 1.8)
Avoided going to public places, such as stores or restaurants	422	74.4%	72.8% (± 4.1)
Avoided small gatherings of people, with family or friends	426	75.1%	75.3% (± 4.0)
Worked from home (among all respondents, regardless of employment status)	223	39.3%	31.4% (± 4.1)
Worn a mask on your face when outside your home	557	98.2%	96.9% (± 1.6)
Traveled by airplane	39	6.9%	6.5% (± 2.6)
Traveled using public transportation, such as bus or train	19	3.4%	5.2% (± 2.0)
Abbreviations: MOE, Margin of Error at the 90% confidence level			

Table 3. Unweighted and weighted state-level seroprevalence of SARS-CoV-2-specific IgG antibodies among adults in Connecticut, overall and by symptoms and risk factors and behaviors.

Characteristics	Sample Size, N	Unweighted Seroprevalence, N (%)	Weighted Seroprevalence, % (MOE)
Overall	567	23 (4.1%)	4.0% (± 2.0)
Race/Ethnicity			
Hispanic	49	3 (6.1%)	12.8% (± 8.0)
Non-Hispanic White	470	16 (3.4%)	2.7% (± 1.7)
Non-Hispanic Black	37	3 (8.1%)	2.6% (± 4.7)
Non-Hispanic Asian	9	*	*
Non-Hispanic Other	5	*	*
Symptoms			
Fever	43	14 (32.6%)	32.4% (± 17.3)
Cough	84	11 (13.1%)	11.4% (± 8.6)
Sore throat	54	5 (9.3%)	10.3% (± 10.7)
New loss of taste or smell [†]	25	*	*
Diarrhea	70	5 (7.1%)	6.9% (± 7.5)
Symptoms aggregate			
Asymptomatic	410	5 (1.2%)	0.6% (± 0.7)
1 or more symptoms	157	18 (11.5%)	11.3% (± 5.9)
2 or more symptoms	67	13 (19.4%)	16.1% (± 11.2)
Risk Factors/Behaviors			
Received coronavirus test	90	13 (14.4%)	19.5% (± 9.5)
Tested positive for coronavirus [†]	11	*	*
Anyone in household (other than respondent) had symptoms of coronavirus	54	12 (22.2%)	19.8% (± 11.8)
Anyone in household (other than respondent) tested positive for coronavirus	16	*	*
Avoided going to public places, such as stores or restaurants	422	17 (4.0%)	4.8% (± 2.4)
Avoided small gatherings of people, with family or friends	426	17 (4.0%)	4.6% (± 2.4)
Worked from home (among all respondents, regardless of employment status)	223	14 (6.3%)	4.2% (± 2.3)
Worn a mask on your face when outside your home	557	23 (4.1%)	4.1% (± 2.0)
Traveled by airplane	39	0 (0.0%)	0.0%
Traveled using public transportation, such as bus or train	19	*	*

* Sample size is <30 and too small to report.

† Though the sample size was too small to report seroprevalence estimates, all 11 of these individuals tested positive for SARS-CoV-2-specific IgG antibodies. Among the 25 individuals who reported loss of taste or smell, 14 individuals tested positive for SARS-CoV-2-specific IgG antibodies.

Abbreviations: MOE, Margin of Error at the 90% confidence level

Table 4. Prevalence of symptomatic illness, risk factors for possible exposure, and adherence to social-distancing behaviors since March 1, 2020 among non-Hispanic Black and Hispanic subpopulation.

Characteristics	Hispanic subpopulation			Non-Hispanic Black subpopulation		
	Unweighted N	Unweighted Proportion, %	Weighted Proportion, % (MOE)	Unweighted N	Unweighted Proportion, %	Weighted Proportion, % (MOE)
Overall	171	N/A	N/A	148	N/A	N/A
Symptoms						
Fever	16	9.4%	10.8% (± 5.6)	7	4.7%	3.9% (± 3.6)
Cough	31	18.1%	17.4% (± 6.4)	18	12.2%	10.1% (± 6.4)
Sore throat	30	17.5%	15.0% (± 6.1)	8	5.4%	4.7% (± 4.6)
New loss of taste or smell	15	8.8%	7.8% (± 4.3)	8	5.4%	4.2% (± 3.8)
Diarrhea	25	14.6%	10.2% (± 5.5)	11	7.4%	5.7% (± 4.7)
Risk Factors/Behaviors						
Received coronavirus test	64	37.4%	36.9 (± 9.6)	54	36.5%	31.0% (± 10.5)
Tested positive for coronavirus (out of all participants, regardless of prior testing)	10	5.8%	6.2% (± 3.8)	9	6.1%	3.9% (± 4.7)
Anyone in household (other than respondent) had symptoms of coronavirus	28	16.4%	20.6% (± 6.8)	6	4.1%	2.1% (± 2.1)
Anyone in household (other than respondent) tested positive for coronavirus	15	8.8%	9.3% (± 4.6)	3	2%	2.0% (± 2.7)
Avoided going to public places, such as stores or restaurants	139	81.3%	79.2% (± 7.6)	96	64.9%	63.8% (± 10.5)
Avoided small gatherings of people, with family or friends	140	81.9%	81.6% (± 6.9)	108	73%	75.4% (± 9.2)
Worked from home (among all respondents, regardless of employment status)	42	24.6%	11.8% (± 5.7)	48	32.4%	17.8% (± 9.0)
Worn a mask on your face when outside your home	168	98.2%	97.7 (± 2.8)	145	98%	96.5% (± 4.0)

Traveled by airplane	11	6.4%	4.8% (± 3.3)	6	4.1%	4.0% (± 4.8)
Traveled using public transportation, such as bus or train	11	6.4%	13.1% (± 5.5)	16	10.8%	23.7% (± 7.5)
Abbreviations: MOE, Margin of Error at the 90% confidence level						